Objective To observe the therapeutic effect of human umbilical cord Wharton's jelly mesenchymal stem cells (WJ-MSC) transplantation on ischemic cardiac disease. Methods Thirty patients with cardiac insufficiency due to ischemic heart disease admitted to Chinese PLA General Hospital from December 2010 to January 2012 were randomly divided into treatment group and control group (15 in each group). WJ-MSC(2×107) were prepared. Patients in treatment group underwent coronary arteriography and 10 ml MSC (2×107) suspension transplantation. Those in control group underwent coronary arteriography and were injected with 10 ml 0.9%sodium chloride. Safety of treatment was observed according to their ECG and laboratory test, their heart function was assessed according to the UCG, their quality of life was assessed according to the SF-36 health scale 3 and 6 months after operation. Severe adverse clinical events were recorded. Results No significant difference was observed in laboratory test and adverse clinical events during the treatment and follow-up periods between the two groups. The LVEDV and LVESV were significantly lower whereas the LVEF was significantly higher in treatment group than in control group 3 and 6 months after operation than before operation (P<0.05). No significant change in LVEDV, LVESV and LVEF was observed in control group (P>0.05). The scores of physical function and general health were significantly increased in the two groups 3 and 6 months after operation than before operation (P <0.05), which were significantly higher in treatment group 6 months after operation than in control group 3 months after operation (P < 0.05). A significant difference was found in the general health scores between the two groups (P < 0.05). Conclusion Coronary WJ-MSC transplantation can improve the cardiac function in patients with ischemic heart disease and is thus a safe and effective treatment modality for ischemic heart disease.% 目的观察人脐带华通胶间充质干细胞冠脉移植治疗缺血性心脏病的临床疗效。方法选择解放军总医院2010年12月-2012年1月住院的缺血性心脏病心功能不全患者30例，随机分为治疗组和对照组各15例。制备脐带华通胶间充质干细胞，治疗组行冠脉造影并移植10 ml干细胞悬液(细胞数2×107)，对照组行冠脉造影并注射10 ml 0.9%氯化钠注射液。治疗前、术后3月及6月分别复查心电图与实验室指标观察治疗安全性，复查超声心动图评价心功能，行SF-36健康量表评价生活质量，并记录严重不良临床事件。结果治疗及随访期间两组实验室检查及临床不良事件发生率差异无统计学意义。治疗组术后3月及6月左室舒张末容量和左室收缩末容量均较术前显著减小，左室射血分数较术前显著提高(P＜0.05)；对照组各指标无明显变化。SF-36健康量表评分治疗组与对照组术后3月、6月较治疗前身体功能及总体健康评分均有显著提高(P＜0.05)，治疗组术后6月较术后3月评分改善仍有统计学意义(P＜0.05)；组间差异比较显示总体健康评分两组差异有统计学意义(P＜0.05)。结论冠脉内移植脐带华通胶间充质干细胞可改善缺血性心脏病患者心功能，是一种安全有效的治疗选择。
展开▼
